Recently, it was demonstrated that specific inhibition of GSK3β (but not of GSK3α) reduced the BACE1-mediated cleavage of APP, reducing neuritic plaque formation and alleviating memory deficits in an AD transgenic mouse model [76]. Here, GSK3A is linked to Alzheimer disease.